Oncology Institute, Inc. (TOI)
CIK 1799191 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 101.9M shares as of Jul 30, 2026 (10-Q).
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Common Warrants | 8.2M | $1.198 | — | — |
| Public Warrants | 5.7M | $11.5 | — | — |
| Pre Funded Warrants | 2.9M | $0.0001 | — | — |
| Private Warrants | 2.2M | not tagged | — | — |
| Public and Private Warrants | not tagged | not tagged | 5y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 5.8M underlying shares, as reported Sep 30, 2021 (10-Q/A).
Rough fully diluted estimate: 107.7M = 101.9M O/S + 5.8M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Facility Agreement | $110.0M | $85.9M | $8.567 | 4% | ~12.8M sh |
If every note above converted at its tagged price: ~12.8M new shares on 101.9M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 101.9M | Jul 30, 2026 |
| + Common Warrants (if exercised) | 8.2M | Jun 30, 2026 |
| + Public Warrants (if exercised) | 5.7M | Jun 30, 2026 |
| + Pre Funded Warrants (if exercised) | 2.9M | Mar 24, 2025 |
| + Private Warrants (if exercised) | 2.2M | Jun 30, 2026 |
| + Facility Agreement (if fully converted) | 12.8M | Aug 9, 2022 |
| Fully diluted estimate | 133.8M | +31.3% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 2 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full TOI workspace